At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Second line (2L) afatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
In Brief
An observational study evaluating Second line (2L) afatinib and Second line chemotherapy for Squamous Non-small Cell Lung Cancer. Completed, enrolled 200 participants across 1 site.
Detailed Summary
This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Non-small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartMay 2020
Primary CompletionMay 2020
First PostedSep 2020
TodayJul 2026
First PostedSep 17, 2020
Enrollment StartMay 8, 2020
Primary CompletionMay 18, 2020
TodayJul 2, 2026
Enrollment to primary: 10 daysPosted 5.8 years ago
Interventions
Second line (2L) afatinibdrug
Afatinib
Second line chemotherapydrug
Chemotherapy